Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ZVSA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-1458.04
vs -38.54
Q3.23
N/A
-31.47
vs -80.34
Q4.23
N/A
-13.68
vs -0.39
Q1.24
N/A
-4.53
vs -135.88
Q2.24
N/A
-3.31
vs -1458.04
Q3.24
N/A
-2.43
vs -31.47
Q4.24
N/A
-1.31
vs -13.68
Q1.25
N/A
-0.73
vs -4.53
Q2.25
N/A
-0.40
vs -3.31
Q3.25
N/A
-0.25
vs -2.43
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
15.6K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 15.6K
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
-391%
-3.91
vs -0.04
Q3.23
-15%
-0.15
vs -3.91
Q4.23
-120%
-1.20
vs -0.15
Q1.24
-25%
-0.25
vs -1.20
Q2.24
-32%
-0.32
vs -0.25
Q3.24
-34170%
-341.70
vs -0.32
Q4.24
0%
-0.00
vs -341.70
Q1.25
-28%
-0.28
vs -0.00
Institutionnal Ownership
globenewswire.com
12 hours ago
benzinga.com
13 hours ago
Quote Panel
Key Metrics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
Relative Strenght
0
Volume Buzz
-100%
Earning Acce
Yes
Dist 52w H.
95%Relative Strength
ZVSA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
-8958%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available